Impact of enteral nutrition during chemotherapy on chemotherapy-related toxicity and response in patients with advanced esophageal cancers

Impact of enteral nutrition during chemotherapy on chemotherapy-related toxicity and response in patients with advanced esophageal cancers - Impact of enteral nutrition during chemotherapy on chemotherapy-related toxicity and response in patients with advanced esophageal cancers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004483

Enrollment

Registered

2010-10-31

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

An amount of 600ml/day of enteral nutritional supplement(Racol@ )is administerd for patients who receive chemotherapy consisting of 5-FU, cisplatin and adriamycin for advanced esophageal cancers are a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have primary esophageal cancer which is histologically confirmed -Performance status is 0-2 -No serious abnormality in heart, lung, bone marrow, liver, and renal functions -obtain informed consent

Exclusion criteria

Exclusion criteria: Patients who have: -narrowing of esophago-intestinal lumen -Serious milk allergy -Serious abnormality in liver and renal

Design outcomes

Primary

Measure	Time frame
frequency of chemotherapy-related adverse effects	—

Secondary

Measure	Time frame
immune function nutrition status	—

Countries

Japan

Contacts

Public ContactHiroshi Miyata

Graduate School of Medicine, Osaka University Department of Gastroenterological Surgery

+81-6-6879-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026